Expression Pathology Inc.. (9/28/04). "Press Release: EPI Awarded SBIR Grant to Develop Prostate Cancer Liquid Tissue Arrays". Gaithersburg, MD.

	Region	United States (USA)
	Organisation	Expression Pathology Inc. (EPI)
	Organisation 2	Johns Hopkins University
	Product	Liquid Tissue® technology (Expression Pathology)
	Product 2	tissue microarray
	Index term	Expression Pathology–United States (govt): grant, 200409 $142k SBIR Phase I grant for developm of Prostate Cancer Tissue Array tog Johns Hopkins Univ
	Person	Tunon, Peter (Expression Pathology 200501– VP Sales + Marketing)

Expression Pathology, Inc. (EPI) announced that it has received a $142,000 Phase I Small Business Innovation Research (SBIR) grant from the National Institutes of Health to develop a prostate cancer tissue protein array.

Sponsored by the National Cancer Institute, the grant will employ EPI's Liquid Tissue™ technology to create an array of well-characterized primary and secondary prostate cancer tissues in collaboration with Dr. G. Steven Bova, Assistant Professor, Department of Pathology at Johns Hopkins University. The resulting Liquid Tissue™ Prostate Cancer Array will be used to profile several important proteins of interest in prostate malignancies.

"We appreciate the NCI's willingness to support the development of this novel research tool, which addresses the need to rapidly and reliably profile the expression of potential
drug target and biomarker proteins in large sets of interesting diseased and normal tissue", commented Casimir P. Eitner, President and CEO of Expression Pathology, Inc.

"EPI is developing its proprietary Liquid TissueTM and ExCelleratorTM laser microdissection technologies to construct arrays of tissue proteins from formalin-fixed samples that can be quantitatively analyzed by antibody detection methods on standard scanners in a high throughput manner. Our Liquid TissueTM Arrays represent an important breakthrough for protein analysis in well-characterized clinical material."

About Expression Pathology

More information about EPI is available at www.expressionpathology.com. EPI has developed innovative, proprietary techniques that address a major emerging need, the
study of proteins in diseased and normal tissue. Discovery and validation of proteins as drug targets and biomarkers is a primary focus of biotechnology. EPI is leveraging its technologies and world-class "molecular pathology" expertise to develop high-value research consumables and services that (a) facilitate more cost-effective analysis of proteins across large numbers of diseased and normal tissue and (b) enable for the first time discovery and analysis of proteins in archived tissue collections with known clinical outcomes.

Patient tissue, collected at surgery, biopsy or autopsy, has been preserved in formalin for nearly a century. Collections of such specimens with associated patient histories are available throughout medical research. However, up to now it has been difficult or impossible to analyze formalin-fixed tissue by standard methods of protein analysis. Yet these archived collections are treasure troves for the discovery of relationships between proteins and documented clinical outcomes, such as disease progression, drug response and drug toxicity. EPI has developed new techniques that enable for the first time accurate and high throughput analysis of proteins in archived tissue.

Contact:

Peter Tunon
Vice President, Business Development
p.tunon@expressionpathology.com
Phone: (240)631-7392 (direct, editorial, collaborations, investment)
Phone: (240)977-3654 (main, general inquiries)
9290 Gaither Road
Gaithersburg, MD 20877
www.expressionpathology.com

Record changed: 2011-11-25

Follow Us!

Top News

Upcoming Events

Associations

Partners

Expression Pathology Inc.. (9/28/04). "Press Release: EPI Awarded SBIR Grant to Develop Prostate Cancer Liquid Tissue Arrays". Gaithersburg, MD.

More documents for Expression Pathology Inc. (EPI)